What does this TikTok actually claim?
@descooki warns viewers to avoid semaglutide entirely after a deeply personal experience. She says she was prescribed it for insulin resistance, lost 45 pounds, but claims it destroyed her "whole livelihood." The video includes hashtags suggesting connections to POTS (postural orthostatic tachycardia syndrome) and mentions seeing a cardiologist.
This isn't a clinical analysis. It's a warning from someone who clearly suffered real consequences from taking the medication.
Does semaglutide actually help insulin resistance?
Yes, but it's not FDA-approved specifically for this indication. The SUSTAIN 6 trial (Marso et al., NEJM, 2016) showed semaglutide improved insulin sensitivity in people with type 2 diabetes. A 2022 study by Gastaldelli found 1mg weekly semaglutide reduced HOMA-IR (an insulin resistance measure) by 31% over 68 weeks.
Doctors do prescribe GLP-1 agonists off-label for insulin resistance because the mechanism makes sense. These drugs slow gastric emptying and improve glucose-dependent insulin secretion. But Des is right that weight loss isn't always worth the trade-offs.
Can semaglutide cause heart problems like POTS?
This gets complicated fast. The cardiovascular outcomes trials like SUSTAIN 6 actually showed semaglutide reduced major adverse cardiac events by 26%. But that's in people with established cardiovascular disease, not healthy people losing weight rapidly.
POTS isn't listed as a known semaglutide side effect in clinical trials. However, rapid weight loss from any cause can trigger dysautonomia in susceptible people. The STEP 1 trial (Wilding et al., NEJM, 2021) reported dizziness in 9.9% of participants versus 4.6% on placebo.
Des might be experiencing something real that didn't show up in controlled studies. Individual responses vary wildly, especially with rapid 45-pound weight loss.
What did Des get wrong about the science?
She tells everyone to avoid semaglutide completely, which ignores the substantial evidence base. The SELECT trial (Lincoff et al., NEJM, 2023) followed 17,604 people and found 20% reduction in cardiovascular death, heart attack, and stroke. That's not trivial.
Her experience sounds genuinely awful, but extrapolating from n=1 to "don't do it" for everyone isn't scientifically sound. The STEP trials showed most people (68-84% depending on the study) completed treatment without serious adverse events.
What should you actually know about semaglutide risks?
Des's story illustrates why starting doses and monitoring matter. The standard protocol begins at 0.25mg weekly, increasing by 0.25mg every 4 weeks up to 2.4mg maintenance dose. Jumping too fast causes more side effects.
Common issues include nausea (44% in STEP 1), diarrhea (30%), and fatigue. Serious but rare risks include pancreatitis (0.2% in trials) and gallbladder problems. The FDA requires warnings about thyroid tumors based on rodent studies, though human risk remains unclear.
If you're considering semaglutide for insulin resistance specifically, metformin has decades more safety data and costs $4 per month. GLP-1s work, but they're not magic, and Des's experience shows the downsides can be severe for some people.